A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage

Functional Outcomes of Robotic Prostatectomy Similar to Conventional Prostatectomy

Researchers from Duke University Medical Center and the University of Florida have reported that patients undergoing laparoscopic robotic prostatectomy (LRP) have similar functional outcomes as patients undergoing perineal prostatectomy (PP). The details of this study were presented at the 2007 meeting of the American Urological Association in May.[1]

The Da Vinci Robotic Surgical System for performing LRP was introduced in 2000. This technique has become very popular in some medical centers and at the present time it is estimated that more than 10% of all prostatectomies are performed by LRP. The purported advantages of this technique are that it allows surgeons to perform prostatectomy with minimal blood loss and with shorter recovery time. In a recent study from Duke University, LRP was associated with an approximate $1,000 increase in surgical cost over conventional RP but this was offset by lower hospitalization costs. However, there is still controversy over whether or not LRP is superior to conventional RP and no randomized trials have been performed or are being planned. Thus, physicians and patients have to rely on non-randomized comparisons to help decide if LRP is appropriate therapy for prostate cancer. One of the main reasons many younger patients are selecting LRP is the belief that this technique will preserve erectile function. However, there are no data to substantiate this claim.

These authors compared health related quality of life parameters as shown in the following table:

 

Radical Perineal Prostatectomy

Robotic Prostatectomy

Number of Patients

140

137

Median Follow-Up

19.2 months

12.4 months

Median Age

59 years

59 years

Median PreRx PSA

7.4 ng/ml

6.0 ng/ml

Mean Prostate Size

39 gms

46 gms

Gleason <6

45%

53%

pT2 Disease

67%

92%

Med. Urinary Recovery

6.1 months

6.4 months

Recovery to 0-1 pad Usage

3.3 months

3.7 months

Bowel Recovery

1.5 months

3.0 months

Sexual Recovery by 2 years

27%

36%

These authors conclude that longer prospective studies were needed to confirm these observations and to evaluate recurrences.

Comments: These data, as other, do not show major differences in functional outcome between perineal prostatectomy and robotic prostatectomy. Most of the studies at the AUA meeting concerning robotic surgery were observational one arm studies documenting the safety and relative effectiveness of this approach. An interesting study at this meeting evaluated sexual-health misinformation on robotic prostatectomy websites.[2] They reviewed 75 web pages from university and community based practices that performed robotic prostatectomy. They found that one third of these sites had no information on erectile function. The majority of sites stated that robotic surgery had better erectile function outcomes compared to open prostatectomy “despite the absence of scientific data to support these claims.” These authors concluded that “This misinformation is giving patients who are considering radical proatatectomy unrealistic expectations.”

References:

[1] Tseng TY, Fesperman SF, Kuebler HR, et al. Prospective comparison of the health-related quality of life outcomes of radical robotic and perineal prostatectomy. Proceedings of the American Urological Association Annual Meeting 2007; Abstract 10. http://www.abstracts2view.com/aua/authorindex.php

[2] Rojas-Cruz C, Mulhall JP. Sexual health misinformation on robotic prostatectomy websites. Proceedings of the American Urological Association Annual Meeting 2007; Abstract 1034. http://www.abstracts2view.com/aua/authorindex.php

Newsletters
Register in our member center today to receive a monthly newsletter with conference coverage updates.
Learn More »
Practice Resources
Learn how to have our conference coverage on your website.
Learn More »
Related News Stories
Maintenance Rituxan® Is Safe for Follicular Lymphoma (7/8/2008)

Gemcitabine, Rituximab, Oxaliplatin, and Pegfilgrastim Active for Relapsed NHL (6/27/2008)

Lumiliximab and FCR Promising for Relapsed CLL (6/26/2008)

Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia (6/25/2008)

Sprycel® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Tasigna® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Patients with KRAS Mutation Do Not Benefit from EGFR Inhibitors (6/20/2008)

Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer (6/20/2008)

Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure? (6/19/2008)

Radiation Therapy for Prostate Cancer Increases Incidence of AML (6/18/2008)

Quinamed® + ARA-C Effective for Secondary Acute Myeloid Leukemia (6/17/2008)

Statins May Reduce Acute Graft-versus-host Disease (6/17/2008)

Provigil®, a Eugeroic Agent, Improves Severe Cancer-related Fatigue (6/13/2008)

Results of Treating NHL Patients over the Age of 80 Reported at ASCO (6/12/2008)

Single-dose Carboplatin Confirmed as Effective as Radiation Therapy for Stage I Seminoma (6/12/2008)

Dose-dense Chemotherapy Effective for Localized Ewing’s Sarcoma (6/11/2008)

Mayo Clinic Reports Increasing Use of Mastectomy for Early-stage Breast Cancer (6/11/2008)

Brachytherapy May Be Treatment of Choice for Endometrial Cancer (6/10/2008)

Gemzar® Improves Survival in Early Pancreatic Cancer (6/9/2008)

Addition of Tykerb® to Herceptin® Improves Time to Progression in Herceptin Pre-treated Breast Cancer (6/6/2008)

Addition of Avastin® to Taxotere® Improves Progression-free Survival in Advanced HER2-negative Breast Cancer (6/6/2008)

Nexavar® Delays Progression of Heavily Pre-treated NSCLC (6/6/2008)

Acupuncture Reduces Pain after Neck Dissection (6/6/2008)

VePesid®/Platinol® Remains Standard of Care for Small Cell Lung Cancer (6/6/2008)

Blood Test Shows Promise for Early Detection of Lung Cancer (6/6/2008)

Tykerb® Monotherapy Active in HER2-positive Refractory Inflammatory Breast Cancer (6/6/2008)

CDX-110 Vaccine May Improve Survival in Brain Cancer (6/5/2008)

Sites of Relapse in Breast Cancer May Require Biopsy to Accurately Determine HER2 or Hormone Status (6/5/2008)

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Renal Cell Cancer (6/4/2008)

Conventional Chemotherapy Outperforms Xeloda® in Older Breast Cancer Patients (6/4/2008)




© 1998-2007 CancerConsultants.com  All Rights Reserved.